top of page
Browse by category
Search
ASC47 in combination with semaglutide has 56.2% reduction in body weight semaglutide monotherapy
Ascletis Pharma’s ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide demonstrated up to 56.2% greater...
Ascletis reveals pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection
Ascletis Pharma has announced pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies in...
Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...
Browse by tag
bottom of page